

Clinical Trials Study

Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity?

Antonietta Gerarda Gravina, Iacopo Panarese, Maria Consiglia Trotta, Michele D'Amico, Raffaele Pellegrino, Franca Ferraraccio, Marilena Galdiero, Roberto Alfano, Paolo Grieco, Alessandro Federico

Specialty type: Gastroenterology and hepatology

Provenance and peer review: Invited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): B
Grade C (Good): C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Rathnaswami A, India; Valek V, Czech Republic

Received: December 21, 2023

Peer-review started: December 21, 2023

First decision: January 13, 2024

Revised: January 15, 2024

Accepted: February 8, 2024

Article in press: February 8, 2024

Published online: March 7, 2024



Antonietta Gerarda Gravina, Raffaele Pellegrino, Alessandro Federico, Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy

Iacopo Panarese, Franca Ferraraccio, Pathology Division, Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, Naples 80138, Italy

Maria Consiglia Trotta, Michele D'Amico, Marilena Galdiero, Department of Experimental Medicine, Division of Pharmacology, University of Campania Luigi Vanvitelli, Naples 80138, Italy

Roberto Alfano, Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania Luigi Vanvitelli, Naples 80138, Italy

Paolo Grieco, Department of Pharmacy, University of Naples Federico II, Naples 80131, Italy

Corresponding author: Raffaele Pellegrino, MD, Hepatogastroenterology Division, Department of Precision Medicine, University of Campania Luigi Vanvitelli, Via L. de Crecchio, Naples 80138, Italy. raffaele.pellegrino@unicampania.it

Abstract

BACKGROUND

Melanocortin 3 and 5 receptors (*i.e.*, MC₃R and MC₅R) belong to the melanocortin family. However, data regarding their role in inflammatory bowel diseases (IBD) are currently unavailable.

AIM

This study aims to ascertain their expression profiles in the colonic mucosa of Crohn's disease (CD) and ulcerative colitis (UC), aligning them with IBD disease endoscopic and histologic activity.

METHODS

Colonic mucosal biopsies from CD/UC patients were sampled, and immunohistochemical analyses were conducted to evaluate the expression of MC₃R and MC₅R. Colonic sampling was performed on both traits with endoscopic scores (Mayo

endoscopic score and CD endoscopic index of severity) consistent with inflamed mucosa and not consistent with disease activity (*i.e.*, normal appearing mucosa).

RESULTS

In both CD and UC inflamed mucosa, MC₃R (CD: + 7.7 fold *vs* normal mucosa, $P < 0.01$; UC: + 12 fold *vs* normal mucosa, $P < 0.01$) and MC₅R (CD: + 5.5 fold *vs* normal mucosa, $P < 0.01$; UC: + 8.1 fold *vs* normal mucosa, $P < 0.01$) were significantly more expressed compared to normal mucosa.

CONCLUSION

MC₃R and MC₅R are expressed in the colon of IBD patients. Furthermore, expression may differ according to disease endoscopic activity, with a higher degree of expression in the traits affected by disease activity in both CD and UC, suggesting a potential use of these receptors in IBD pharmacology.

Key Words: Melanocortin 3 receptor; Melanocortin 5 receptor; Ulcerative colitis; Crohn's disease; Inflammatory bowel disease

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: This study sought to examine the expression levels of Melanocortin 3 and 5 receptors (MC₃R and MC₅R) in the colons of individuals diagnosed with Crohn's disease and ulcerative colitis. Analysis of tissue samples obtained from both inflamed and non-inflamed sections of the colon revealed a notable increase in the expression of both receptors within inflamed regions compared to non-inflamed areas, with the extent of expression suggesting a potential association with the severity of disease activity. These findings imply that MC₃R and MC₅R may serve as potential targets for pharmacological interventions in the context of inflammatory bowel diseases.

Citation: Gravina AG, Panarese I, Trotta MC, D'Amico M, Pellegrino R, Ferraraccio F, Galdiero M, Alfano R, Grieco P, Federico A. Melanocortin 3,5 receptors immunohistochemical expression in colonic mucosa of inflammatory bowel disease patients: A matter of disease activity? *World J Gastroenterol* 2024; 30(9): 1132-1142

URL: <https://www.wjgnet.com/1007-9327/full/v30/i9/1132.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v30.i9.1132>

INTRODUCTION

The etiology of inflammatory bowel diseases (IBD), predominantly encompassing Crohn's disease (CD) and ulcerative colitis (UC), remains enigmatic, primarily due to the intricate interplay of various factors and molecular pathways. Inhibitors of the tumor necrosis factor (TNF)-induced inflammatory pathway continue to constitute a significant component of the treatment protocols employed in current clinical practice[1,2]. In any case, various lines of evidence have demonstrated that the modulation of the melanocortin system can influence inflammatory pathways, thereby unveiling the therapeutic potential of melanocortins[3-6].

The melanocortin system constitutes a sophisticated and evolutionarily antique network of peptides, encompassing α , β , γ -Melanocyte-Stimulating-Hormone (MSH), and adrenocorticotrophic hormone (ACTH). These peptides stem from a common protein precursor called pro-opiomelanocortin[7]. It functions *via* five melanocortin receptors (MC₁₋₅R) that belong to the family of G protein-coupled receptor proteins, distributed diversely in both animals and humans. They are promiscuously activated by [Nle⁴, DPhe⁷]- α -MSH, α -MSH, β -MSH, γ -MSH, ACTH, and agouti-related protein[3]. The MC₁R receptor exhibits expression within a heterogeneous spectrum of cell types, encompassing fibroblasts, melanocytes, keratinocytes, neutrophils, monocytes, dendritic cells, B lymphocytes, gliocytes, endotheliocytes, and additionally, neoplastic cells. In the context of melanogenesis, it primarily contributes to the synthesis of eumelanin by activating the enzyme tyrosinase. Additionally, its expression is observed in the colon, where it plays a role in gut inflammation in rats [8,9].

In contrast, MC₂R, primarily expressed in the adrenal cortex and adipocytes, is implicated in steroid synthesis[7,10] and does not have a purported role in inflammation. MC₃R displays a comprehensive expression profile within the central nervous system and immune cells, specifically in B lymphocytes and macrophages. Additionally, its presence extends to diverse anatomical locations in the rat, including the gut, heart, and placenta[7,11]. Its primary roles are associated with metabolic control and inflammatory response. MC₄R is located within the vagal nerve afferents to the stomach and small intestine, participating in postprandial functions in mice[7,12].

MC₅R exhibits a primarily widespread distribution and is implicated in the immunomodulation of B-T lymphocytic responses, along with the regulation of secretions from exocrine glands[7,13-19], with no clear available information on its localization and role at the intestinal level. The extent of expression of MC₃R and MC₅R in the colon and their roles in the intestinal microenvironment of IBD are not well understood.

This study aims to assess the immunohistochemical expression of MC₃R and MC₅R in the colons of patients with IBD and to determine whether there is a greater immunohistochemical expression in segments affected by the disease

compared to those with apparently normal mucosa.

MATERIALS AND METHODS

Study design and setting

Patients exhibiting symptoms consistent with and suspected of having IBD (*e.g.*, increased bowel movements, rectal bleeding, abdominal pain) and receiving a specialist recommendation for colonoscopy, subsequently diagnosed with IBD (either CD or UC), were included in the study. The study was carried out at the Hepatogastroenterology Division of the University of Campania Luigi Vanvitelli from January to December 2020. The research adhered to the principles of the Declaration of Helsinki and received approval from the Ethics Committee of the University of Campania Luigi Vanvitelli (protocol code 795 on December 23, 2019).

Inclusion and exclusion criteria

Several inclusion and exclusion criteria were established. IBD participants aged 18 or older, who were treatment-naïve for any IBD, were included. Specifically, patients were required not to have received conventional therapy (*e.g.*, mesalazine, budesonide, conventional immunosuppressants like azathioprine, systemic-acting steroids), advanced therapies such as biologics (*e.g.*, infliximab, adalimumab, ustekinumab), or small molecules (*e.g.*, tofacitinib, filgotinib, upadacitinib).

Furthermore, to prevent study exclusion, all IBD diagnoses had to be confirmed by a pathologist in accordance with current guidelines[20].

Hospitalized patients or those with clinically significant infections (*e.g.*, tuberculosis, SARS-CoV-2, HIV, *Clostridioides difficile*) within the preceding six months, or with clinical or instrumental evidence of neoplasm, were excluded. Additionally, patients with subsequent endoscopic and/or histological diagnoses of ischemic colitis, radiation colitis, microscopic colitis, undetermined colitis, colonic dysplasia, and benign or malignant colonic neoplasms were also excluded from our study. Patients presenting conditions that, according to the investigators' assessment, could potentially introduce bias into the study (for instance, individuals with decompensated comorbidities or those currently experiencing severe acute conditions such as decompensated diabetes or severe cardiovascular disease) were also excluded. Moreover, patients with other digestive diseases (*e.g.*, celiac disease, autoimmune atrophic gastritis) were excluded. Individuals with known psychiatric disorders, legal incapacity to provide informed consent, or, lastly, those with any contraindication to undergoing colonoscopy were omitted.

Collected variables and colonic sampling

The following clinical-demographic variables were recorded: age (in years), gender, weight (in kg), height (in cm), body mass index (in kg/m²), smoking status (*i.e.*, active smoker or non-smoker), IBD type (*i.e.*, CD or UC), and comorbidity.

During a colonoscopy (conducted for diagnostic purposes, as mentioned above, unrelated specifically to this study), in addition to the standard biopsies required by current clinical practice (*i.e.*, two segmental biopsies in the cecum, ascending, transverse, descending, sigmoid colon, and rectum)[21], additional mucosal biopsy samples were obtained for the study. Specifically, two biopsies were taken in colonic/rectal tracts displaying clear signs of mucosal inflammatory involvement (*i.e.*, inflamed mucosa), and two in tracts with endoscopically normal-appearing mucosa. Consequently, for the study's sampling criteria, only patients with a Montreal classification for CD of L2 (colic) or L3 (ileocolonic) were included. In contrast, only patients with E1 (proctitis) or E2 (left colitis, distal colitis) were admitted for UC.

The difference between inflamed and normal-appearing mucosa was made using validated endoscopic scores to evaluate IBD[22]. In detail, in the case of suspected UC (continuous inflammatory involvement without skip lesions and with rectal involvement), the colonic mucosa was assessed using the Mayo endoscopic subscore at the endoscopic examination[23]. We performed biopsies on Mayo endoscopic subscore 0 compatible tracts and Mayo endoscopic subscore ≥ 1 compatible tracts. Colonic mucosa was evaluated using the CD endoscopic index of severity (CDEIS)[24] for suspected CD (*i.e.*, segmental colitis and ileum involvement at retrograde ileoscopy). Biopsies were conducted on tracts with CDEIS < 3 (compatible) and tracts with CDEIS ≥ 3 (consistent). The endoscopic procedures were carried out by a gastroenterologist experienced in IBD digestive endoscopy with extensive casuistry. The histological diagnosis of IBD (*i.e.*, CD or UC) was established based on histological criteria validated by current European guidelines[20].

Samples management and immunohistochemistry evaluations

As previously mentioned, supplementary histological and immunohistochemical investigations were conducted on the latter. In addition to routine assessments on the same samples, these investigations aimed to identify the expression profiles of MC₃R and MC₅R. Following the collection of biopsy samples, they were fixed in formalin and subsequently embedded in paraffin. Sections of 5 μm were cut and then stained with haematoxylin-eosin for morphological evaluation. Two slides were chosen for each patient, one representing healthy tissue and the other depicting the site of the inflammatory process. Immunohistochemical staining for anti-MC₃R and anti-MC₅R antibodies was carried out on these slides. For this purpose, sections with a thickness of 4-5 μm were prepared, and paraffin was removed using a xylene substitute (Hemo-De; Thermo-Fisher Scientific, Darmstadt, Germany). The immunohistochemistry procedure was conducted using the BenchMark Automated IHC/ISH slide staining system, following the manufacturer's instructions (BenchMark Ventana, Tucson, AZ, United States)[25].

In brief, tissue sections underwent sequential rehydration with ethanol gradient washes, pre-heating, and staining with haematoxylin and eosin. Citrate antigen retrieval was conducted by placing slides in citrate buffer (0.1 M citric acid

monohydrate and 0.1 M sodium citrate; pH 6) in a water-filled steamer for 20 min. Endogenous peroxidase activity was quenched in a 3% hydrogen peroxide aqueous solution for 15 min, and non-specific antibody binding was inhibited by one-hour incubation at room temperature in a blocking solution (1% BSA, 0.2% powdered skim milk, 0.3% Triton-X 100 in PBS).

Sections were incubated with specific anti-MC₃R (1:100 in blocking solution; ab140864, Abcam, United Kingdom) and anti-MC₅R (1:100 in blocking solution; sc-28994, Santa Cruz, United States) antibodies, washed with PBS, incubated with biotin-conjugated secondary antibodies and DBA (avidin-biotin-peroxidase complex, Milan, Italy), and DAB (3,3-diaminobenzidine) reaction was employed to visualize the specific antigens in each section[25]. Slides were counterstained with haematoxylin. Immunostaining analysis was conducted by an expert pathologist (intraobserver variability 5%). As no existing data on the immunohistochemical expression of MC₃R and MC₅R in colonic mucosa are available in the literature, all staining was assessed, with particular attention to the inflammatory infiltrate. The data are expressed as a percentage \pm SEM (standard error of the mean) of MC₃R or MC₅R positive cells relative to the total cells counted.

Statistical analysis

Descriptive statistics were employed for data presentation. Continuous variables were reported as the median (interquartile range). The receptor expression profile was presented as a percentage \pm SEM. Data distribution was assessed to determine whether parametric or non-parametric tests were more appropriate. The comparison between ordinal and continuous variables across groups was conducted using the Mann-Whitney *U*-test.

The accepted level of statistical significance was set at a two-tailed *P*-value less than 0.05. IBM® SPSS® was utilized as the software for data analysis, while GraphPad Prism 9® was used for graph processing.

RESULTS

Characteristics of included patients

Forty-six patients underwent initial screening for inclusion criteria to be enrolled in the study; however, twenty did not subsequently meet the inclusion criteria, resulting in a final enrolment of twenty-six patients overall. Among the twenty excluded patients, the reasons for exclusion were as follows: Three patients had a diagnosis of significant comorbidity (gastric cancer in one case and systemic sclerosis in two cases), in five cases, exclusion was dictated by the diagnosis of colonic dysplasia, in two cases by the diagnosis of non-specific colitis, in one case of ischemic colitis, and finally, nine patients had a completely negative colonoscopy.

Of the 26 patients finally enrolled, 13 (50%) had CD, and 13 (50%) had UC. The overall median age was 49.5 (40.75-69.5) years. Table 1 displays the clinical and demographic characteristics of included patients, and categorized on IBD type.

Microscopic examination of specimens with haematoxylin-eosin staining

In patients with CD, haematoxylin-eosin staining revealed surface erosion and de-epithelialisation in the colonic mucosa, particularly on the right side. This was accompanied by a dense chronic inflammatory infiltrate and histological activity featuring cryptitis. Additionally, non-necrotising epithelioid granulomas were observed.

Conversely, in patients with UC, the colonic mucosa displayed erosions of the surface epithelium, characterized by a significant reduction in the glandular muciparous quota and distortion of crypt architecture. Within the lamina propria, a severe chronic inflammatory infiltrate exhibited histological activity, including cryptitis and cryptic microabscesses.

In all examined samples from individuals with IBD, no signs of epithelial dysplasia were evident (Figures 1-4).

Immunohistochemical expression of MC₃R and MC₅R is evident in the colon affected by IBD and could potentially vary based on endoscopic disease activity

All patients, 100% (26/26), tested positive for MC₃R, and positivity was observed in all colonic samples within the segments affected by the disease (Figures 1 and 2). Interestingly, this positivity was not observed in the tracts where the disease was inactive (Figures 1 and 2).

Furthermore, immunohistochemistry for MC₃R in CD samples exhibited cytoplasmic staining at the level of both mononuclear and polymorphonuclear inflammatory infiltrates, with a significant prevalence in "pathological" (*i.e.*, inflamed mucosa) slides compared to healthy tissue obtained from normal-appearing mucosa (fold: + 7.7, *P* < 0.01 *vs* normal mucosa; Figure 1).

Similarly, MC₃R labelling in UC samples was significantly higher in inflamed mucosa (fold: + 12, *P* < 0.01 *vs* normal mucosa), particularly at the level of the rectal and sigmoidal tracts (Figure 2).

MC₅R tested positive in 22 out of 26 patients (84%), and like MC₃R, it exhibited positivity in tracts affected by both CD (Figure 3) and UC (Figure 4).

Similar to MC₃R, immunohistochemistry for MC₅R displayed cytoplasmic staining at the mononuclear and polymorphonuclear inflammatory infiltrate levels, with a significant prevalence in "pathological" slides compared to healthy tissue. Moreover, in favorable cases, MC₅R demonstrated a higher intensity staining than MC₃R (CD fold: + 5.5, *P* < 0.01 *vs* normal mucosa. UC fold: + 8.1, *P* < 0.01 *vs* normal mucosa).

Table 1 Clinical and demographic characteristics of patients in Crohn's disease and ulcerative colitis groups.

Parameter	CD (n = 13)	UC (n = 13)	P value ¹
Age (yr)	49 (45-66.5)	50 (30.5-81)	0.801
Gender			0.762
Male	8 (61.5)	7 (53.8)	
Female	5 (38.5)	6 (46.2)	
Body weight (kg)	63.2 (58-68)	81 (79-86.5)	0.001
Body height (cm)	174 (159.5-185.5)	165 (158.5-178)	0.489
BMI (kg/m ²)	23 (18-25.5)	30 (24-33)	0.002
Smoking status			0.762
Active smoker	2 (15.4)	1 (7.7)	
Non-smoker	11 (84.6)	12 (92.3)	
Comorbidity			
Hypertension	2 (15.4)	1 (7.7)	0.724

¹P values were acquired by examining the differences in individual variables between the two groups. Data are presented as median (interquartile range or percentages). CD: Crohn's disease; UC: Ulcerative colitis.




Figure 1 Melanocortin 3 receptor expression in samples from individuals with Crohn's disease. A and B: Representative histological sections stained with haematoxylin-eosin for normal (A) and inflamed (B) mucosa. The blue arrow highlights the dense chronic inflammatory infiltrate, while the black arrow indicates histological activity with cryptitis and microabscesses; C and D: Immunohistochemical staining in the former (C) and latter (D) is also depicted. The rate of Melanocortin 3 receptor (MC₃R) cell positivity, as determined by immunohistochemistry, was significantly higher in the inflamed mucosa compared to the normal mucosa; E: The data are presented as % ± SEM of MC₃R positive cells relative to the total cells counted. Scale bar = 500 μm. ^aP < 0.01.

DISCUSSION

The present study suggests a distinctive expression pattern of MC₃R and MC₅R in the colorectum of patients with IBD. It proposes that their expression could be hypothetically linked to disease activity, indicating a heightened presence in segments of the large bowel affected by histological damage. To the best of our knowledge, such a profile of immunohistochemical expression has not been previously reported[7].

The current evidence on the expression profile of melanocortin receptors at the level of body tissues is, in fact, not yet wholly conclusive[7]. Still, it needs to be studied, and in particular, the evidence on the relationship between MC₃R and MC₅R receptors and IBD is scarce[9]. However, our results do not fully clarify the role of these two types of receptors in specific inflammatory pathogenesis. A mechanistic breakthrough is necessary to assess the mechanisms through which




Figure 2 Melanocortin 3 receptor expression in samples from individuals with ulcerative colitis. A and B: Representative histological sections stained with haematoxylin-eosin for normal (A) and inflamed (B) mucosa. The blue arrow highlights the dense chronic inflammatory infiltrate, while the black arrow indicates histological activity with cryptitis; C and D: Immunohistochemical staining in the former (C) and latter (D) is also presented. The rate of Melanocortin 3 receptor (MC₃R) cell positivity, determined through immunohistochemistry, was significantly higher in the inflamed mucosa compared to the normal mucosa; E: The data are expressed as % ± SEM of MC₃R positive cells relative to the total cells counted. Scale bar = 500 μm. ^a*P* < 0.01.




Figure 3 Melanocortin 5 receptor expression in samples from individuals with Crohn's disease. A and B: Representative histological sections stained with haematoxylin-eosin for normal (A) and inflamed (B) mucosa. The blue arrow highlights the dense chronic inflammatory infiltrate, while the black arrow indicates histologic activity with microabscesses; C and D: Immunohistochemical staining in the former (C) and latter (D) is also presented. The rate of Melanocortin 5 receptor (MC₅R) cell positivity, determined through immunohistochemistry, was significantly higher in the inflamed mucosa compared to the normal mucosa; E: The data are expressed as % ± SEM of MC₅R positive cells relative to the total cells counted. Scale bar = 500 μm. ^a*P* < 0.01.

these receptors may exert immunomodulatory effects.

Numerous studies have previously highlighted the participation of MC₃R in inflammation. Furthermore, various molecules with the capability to engage with MC₃R have shown anti-inflammatory characteristics linked to this receptor. Specifically, fragments of ACTH that activate MC₃R have demonstrated the ability to inhibit cytokine synthesis in peritoneal macrophages, thereby indirectly impeding neutrophilic diapedesis[26]. Furthermore, at the cardiac level, where macrophages express MC₃R, the application of agonists during instances of acute myocardial infarction in mice has exhibited a protective function, even amidst reperfusion. This demonstration revealed that the protection was associated




Figure 4 Melanocortin 5 receptor expression in samples from individuals with ulcerative colitis. A and B: Representative histological sections stained with haematoxylin-eosin for normal (A) and inflamed (B) mucosa. The white arrow highlights the dense chronic inflammatory infiltrate in inflamed mucosa; C and D: Immunohistochemical staining in the former (C) and latter (D) is also presented. The rate of Melanocortin 5 receptor (MC₅R) cell positivity, determined through immunohistochemistry, was significantly higher in the inflamed mucosa compared to the normal mucosa; E: The data are expressed as % ± SEM of MC₅R positive cells relative to the total cells counted. Scale bar = 500 μ m. * $P < 0.01$.

with a reduction in systemic and local inflammatory markers, including interleukin-1 and myeloperoxidase[27]. In other mice models, the same protective effects were identified in gouty arthritis[28]. The anti-inflammatory function of MC₃R has been substantiated in the context of metabolic syndrome in mice lacking MC₃R, regardless of weight gain[29].

The MC₅R receptor is predominantly linked to the modulation of immune-mediated inflammation and the initiation of the JAK2-mediated pathway[30]. This latter pathway has been effectively utilized pharmacologically for the treatment of UC[31].

MC₅R has been associated with ocular immunity, although its involvement in inflammatory responses remains incompletely understood. Selective agonists of MC₅R have demonstrated promising positive effects in conditions characterized by immune dysregulation[32].

Earlier studies have attempted to assess the pharmacological role of certain melanocortin receptors in IBD. This includes PL-8177 (a selective MC₁R ligand), which, in a study involving induced murine colitis, demonstrated the ability to reduce bowel inflammation with effects comparable to sulfasalazine[9].

Upon observing a noteworthy expression of the receptors in the impaired tissue, it is tempting to speculate that, from a translational standpoint, the expression of MC₃R and MC₅R may not correspond to an activity adequate for resolving colonic inflammation. Therefore, substantial stimulation with specific agonists may be necessary to overcome the burst of inflammation underlying IBD. This considers their reviewed role in fighting inflammation in several conditions[9,32-35].

The capacity of these receptors to respond to various endogenous agonists such as [Nle⁴, DPh⁷]- α -MSH, α -MSH, and γ -MSH may underscore the importance of regarding these receptors as crucial responders to inflammation. However, Montero-Melendez[36], in a systematic review, has emphasized the concept that α -MSH can serve as an excellent illustration of "endogenous-based pro-resolving therapy". Unlike biological drugs targeted against a single entity, this molecule can simultaneously modulate interleukin-1 β , prostaglandins, TNF- α , cell adhesion molecules, and inflammatory cells such as monocytes, macrophages, and neutrophils, as previously elucidated.

Given a well-determined receptor expression higher in patients with CD and UC samples, one would argue that new MC₃R-MC₅R drugs could be molecules in rectal and gastro-resistant oral formulations. However, this is a remote hypothesis that should be considered only after further preclinical studies demonstrate mechanistically a genuine anti-inflammatory potential for IBD. It is known that a proportion of IBD patients experience primary failure or secondary loss of response to several lines of biological therapy. Therefore, as a consequence, the exploration of new therapeutic agents and, particularly, new therapeutic mechanisms for IBD is desirable. Presently, there are specific MC₃R and MC₅R agonists already developed and documented in the literature, which could be regarded as potential therapeutic agents. Specifically, DTrp- α -MSH and the macrocyclic peptide PG911 are well-established agonists at hMC₃R and hMC₅R, respectively[37,38].

In CD, the data in this study are, by its design, restricted to patients with disease extension L2 or L3 according to the Montreal classification and, in any case, exclusively within the colonic microenvironment. Consequently, it is important to consider this observation and the non-applicability of the data to ileal or ileojejunal locations or other non-colonic disease localizations. Therefore, a greater understanding of the expression of these receptors in the small intestine is absolutely necessary as an additional piece in this already limited research context. A preliminary study by Gantz *et al*[39] suggested MC₃R intestinal expression (specifically in the duodenum) through northern blot hybridization and

polymerase chain reaction. However, subsequently, there haven't been robust studies that thoroughly detail the expression profiles of these two receptors in different gastrointestinal segments.

This study possesses several strengths. The majority of investigations concerning the melanocortin system and IBD have been conducted using pre-clinical cell models or mouse models[7]. The assessment of MC₃R-MC₅R expression profiles was conducted in treatment-naïve patients diagnosed with IBD for the first time and highly selected for comorbidities. This implies that the evaluation was carried out in patients with a diminished risk of bias attributable to prior treatments or comorbidities. However, this study is subject to several limitations. Firstly, the patient sample needs to be expanded to encompass individuals expressing varying levels of these receptors. Additionally, the correlation between these expression profiles and the IBD therapies undertaken by patients should be explored in future investigations. Moreover, it is noteworthy that this study, despite its novelty, did not incorporate assessments through polymerase chain reaction or Western blot analysis. Subsequent studies should consider incorporating these techniques to thoroughly evaluate the expression of MC₃R and MC₅R. Nevertheless, the high specificity demonstrated by the MC₃R-MC₅R kits employed in our study leads us to presume that analyses of this nature would likely corroborate the observed expression profile at the colonic level.

Moreover, it could be intriguing from a translational standpoint to investigate whether there exists a correlation between MC₃R-MC₅R expression and endoscopic disease activity, assessed using validated tools and scores[22], aiming to identify a potential direct association. However, it is crucial to highlight that the sample size within our dataset impedes the undertaking of correlation analyses essential for revealing statistically significant findings.

Therefore, we await the execution of future, more extensive studies and randomized double-blind trials to test new melanocortin agonists and verify their immunomodulatory potentialities.

CONCLUSION

In conclusion, this study delves into the distinctive immunohistochemical expression patterns of MC₃R and MC₅R in the colorectum of patients with IBD. The observed expression of these receptors potentially appears to be linked to disease activity, with heightened presence in segments of the large bowel affected by histological damage. This unique expression profile has not been previously reported, indicating a novel avenue for exploration in the context of IBD and the melanocortin system.

However, the study has limitations, such as a small sample size and a lack of correlation analyses with endoscopic disease activity. Future investigations with larger cohorts, incorporating mechanistic and molecular analyses like PCR and Western blot, could provide a more comprehensive understanding. Additionally, the observed expression patterns prompt consideration for the development of specific MC₃R and MC₅R ligands as potential therapeutic agents for IBD, necessitating further exploration in preclinical and clinical settings.

ARTICLE HIGHLIGHTS

Research background

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), present complex etiologies. The modulation of the melanocortin system, involved in inflammatory pathways, offers therapeutic potential.

Research motivation

Understanding the immunohistochemical expression of melanocortin 3 and 5 receptors (MC₃R and MC₅R) in colonic mucosa of IBD patients is crucial for unraveling potential immunomodulatory roles.

Research objectives

To assess immunohistochemical expression patterns of MC₃R and MC₅R in colons of IBD patients, exploring associations with disease activity.

Research methods

A study involving treatment naïve IBD patients was conducted. Biopsies were taken from inflamed and normal mucosa, and immunohistochemical staining for MC₃R and MC₅R was performed.

Research results

Both MC₃R and MC₅R exhibited significant positivity in inflamed mucosa compared to normal mucosa, suggesting a potential correlation with disease activity. The expression pattern was distinct in CD and UC samples.

Research conclusions

The study proposes a unique expression profile of MC₃R and MC₅R in IBD, indicating potential links to disease activity. However, limitations include a small sample size and a lack of correlation analyses with endoscopic disease activity.

Research perspectives

Future investigations with larger cohorts and mechanistic analyses, such as polymerase chain reaction and Western blot, are necessary for a comprehensive understanding. The observed expression patterns suggest potential avenues for developing specific MC₃R and MC₅R ligands as therapeutic agents for IBD, warranting exploration in preclinical and clinical settings.

FOOTNOTES

Author contributions: Gravina AG, Panarese I, and Trotta MC were responsible for literature collection, initial manuscript writing, conceptualization of tables and figures, and made equal contributions to this work; the analysis was conducted by Gravina AG, Panarese I, Trotta MC, Panarese I, and Pellegrino R; all authors contributed to the conceptualization of the text's structure, critically reviewed the manuscript for significant intellectual content, and read and approved the final version of the manuscript.

Institutional review board statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of University of Campania Luigi Vanvitelli (Protocol code 795 on December 23, 2019).

Clinical trial registration statement: This study has been assigned the protocol code "AOU 26599/19" in the Luigi Vanvitelli University Hospital's records.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: The authors declare no conflicts of interest for this article.

Data sharing statement: No additional data are available.

CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Italy

ORCID number: Antonietta Gerarda Gravina [0000-0001-8049-0115](https://orcid.org/0000-0001-8049-0115); Iacopo Panarese [0000-0002-7292-5219](https://orcid.org/0000-0002-7292-5219); Maria Consiglia Trotta [0000-0001-9813-5955](https://orcid.org/0000-0001-9813-5955); Michele D'Amico [0000-0002-6899-0595](https://orcid.org/0000-0002-6899-0595); Raffaele Pellegrino [0000-0001-5074-230X](https://orcid.org/0000-0001-5074-230X); Paolo Grieco [0000-0002-6854-8123](https://orcid.org/0000-0002-6854-8123); Alessandro Federico [0000-0002-0885-0793](https://orcid.org/0000-0002-0885-0793).

Corresponding Author's Membership in Professional Societies: United European Gastroenterology; Società Italiana Di Gastroenterologia Ed Endoscopia Digestiva.

S-Editor: Lin C

L-Editor: A

P-Editor: Yu HG

REFERENCES

- 1 **Harbord M**, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; European Crohn's and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. *J Crohns Colitis* 2017; **11**: 769-784 [PMID: [28513805](https://pubmed.ncbi.nlm.nih.gov/28513805/) DOI: [10.1093/ecco-jcc/jjx009](https://doi.org/10.1093/ecco-jcc/jjx009)]
- 2 **Torres J**, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. *J Crohns Colitis* 2020; **14**: 4-22 [PMID: [31711158](https://pubmed.ncbi.nlm.nih.gov/31711158/) DOI: [10.1093/ecco-jcc/jjz180](https://doi.org/10.1093/ecco-jcc/jjz180)]
- 3 **Holder JR**, Haskell-Luevano C. Melanocortin ligands: 30 years of structure-activity relationship (SAR) studies. *Med Res Rev* 2004; **24**: 325-356 [PMID: [14994367](https://pubmed.ncbi.nlm.nih.gov/14994367/) DOI: [10.1002/med.10064](https://doi.org/10.1002/med.10064)]
- 4 **Panaro BL**, Tough IR, Engelstoft MS, Matthews RT, Digby GJ, Møller CL, Svendsen B, Gribble F, Reimann F, Holst JJ, Holst B, Schwartz TW, Cox HM, Cone RD. The melanocortin-4 receptor is expressed in enteroendocrine L cells and regulates the release of peptide YY and glucagon-like peptide 1 in vivo. *Cell Metab* 2014; **20**: 1018-1029 [PMID: [25453189](https://pubmed.ncbi.nlm.nih.gov/25453189/) DOI: [10.1016/j.cmet.2014.10.004](https://doi.org/10.1016/j.cmet.2014.10.004)]
- 5 **Rajora N**, Boccoli G, Catania A, Lipton JM. alpha-MSH modulates experimental inflammatory bowel disease. *Peptides* 1997; **18**: 381-385

- [PMID: 9145424 DOI: 10.1016/S0196-9781(96)00345-2]
- 6 **Oktar BK**, Ercan F, Yeğen BC, Alican I. The effect of alpha-melanocyte stimulating hormone on colonic inflammation in the rat. *Peptides* 2000; **21**: 1271-1277 [PMID: 11035215 DOI: 10.1016/S0196-9781(00)00269-2]
 - 7 **Gravina AG**, Pellegrino R, Durante T, Palladino G, Imperio G, D'Amico G, Trotta MC, Dallio M, Romeo M, D'Amico M, Federico A. The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials. *Cells* 2023; **12** [PMID: 37508552 DOI: 10.3390/cells12141889]
 - 8 **Maaser C**, Kannengiesser K, Specht C, Lügering A, Brzoska T, Luger TA, Domschke W, Kucharzik T. Crucial role of the melanocortin receptor MC1R in experimental colitis. *Gut* 2006; **55**: 1415-1422 [PMID: 16543288 DOI: 10.1136/gut.2005.083634]
 - 9 **Spana C**, Taylor AW, Yee DG, Makhlina M, Yang W, Dodd J. Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases. *Front Pharmacol* 2018; **9**: 1535 [PMID: 30692924 DOI: 10.3389/fphar.2018.01535]
 - 10 **Wang W**, Guo DY, Lin YJ, Tao YX. Melanocortin Regulation of Inflammation. *Front Endocrinol (Lausanne)* 2019; **10**: 683 [PMID: 31649620 DOI: 10.3389/fendo.2019.00683]
 - 11 **Hiramoto K**, Kobayashi H, Ishii M, Sato E, Inoue M. Increased alpha-melanocyte-stimulating hormone (alpha-MSH) levels and melanocortin receptors expression associated with pigmentation in an NC/Nga mouse model of atopic dermatitis. *Exp Dermatol* 2010; **19**: 132-136 [PMID: 19889022 DOI: 10.1111/j.1600-0625.2009.00988.x]
 - 12 **Gautron L**, Lee C, Funahashi H, Friedman J, Lee S, Elmquist J. Melanocortin-4 receptor expression in a vago-vagal circuitry involved in postprandial functions. *J Comp Neurol* 2010; **518**: 6-24 [PMID: 19882715 DOI: 10.1002/cne.22221]
 - 13 **Catania A**. Neuroprotective actions of melanocortins: a therapeutic opportunity. *Trends Neurosci* 2008; **31**: 353-360 [PMID: 18550183 DOI: 10.1016/j.tins.2008.04.002]
 - 14 **Videira IF**, Moura DF, Magina S. Mechanisms regulating melanogenesis. *An Bras Dermatol* 2013; **88**: 76-83 [PMID: 23539007 DOI: 10.1590/S0365-05962013000100009]
 - 15 **Lam CW**, Getting SJ. Melanocortin receptor type 3 as a potential target for anti-inflammatory therapy. *Curr Drug Targets Inflamm Allergy* 2004; **3**: 311-315 [PMID: 15379600 DOI: 10.2174/1568010043343606]
 - 16 **Loos RJ**, Lindgren CM, Li S, Wheeler E, Zhao JH, Prokopenko I, Inouye M, Freathy RM, Attwood AP, Beckmann JS, Berndt SI; Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, Jacobs KB, Chanock SJ, Hayes RB, Bergmann S, Bennett AJ, Bingham SA, Bochud M, Brown M, Cauchi S, Connell JM, Cooper C, Smith GD, Day I, Dina C, De S, Dermitzakis ET, Doney AS, Elliott KS, Elliott P, Evans DM, Sadaf Farooqi I, Froguel P, Ghorji J, Groves CJ, Gwilliam R, Hadley D, Hall AS, Hattersley AT, Hebebrand J, Heid IM; KORA, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Herrera B, Hinney A, Hunt SE, Jarvelin MR, Johnson T, Jolley JD, Karpe F, Keniry A, Khaw KT, Luben RN, Mangino M, Marchini J, McArdle WL, McGinnis R, Meyre D, Munroe PB, Morris AD, Ness AR, Neville MJ, Nica AC, Ong KK, O'Rahilly S, Owen KR, Palmer CN, Papadakis K, Potter S, Pouta A, Qi L; Nurses' Health Study, Randall JC, Rayner NW, Ring SM, Sandhu MS, Scherag A, Sims SK, Song K, Soranzo N, Speliotes EK; Diabetes Genetics Initiative, Syddall HE, Teichmann SA, Timpson NJ, Tobias JH, Uda M; SardiNIA Study, Vogel CI, Wallace C, Waterworth DM, Weedon MN; Wellcome Trust Case Control Consortium, Willer CJ; FUSION, Wraight, Yuan X, Zeggini E, Hirschhorn JN, Strachan DP, Ouwehand WH, Caulfield MJ, Samani NJ, Frayling TM, Vollenweider P, Waeber G, Mooser V, Deloukas P, McCarthy MI, Wareham NJ, Barroso I, Jacobs KB, Chanock SJ, Hayes RB, Lamina C, Gieger C, Illig T, Meitinger T, Wichmann HE, Kraft P, Hankinson SE, Hunter DJ, Hu FB, Lyon HN, Voight BF, Ridderstrale M, Groop L, Scheet P, Sanna S, Abecasis GR, Albai G, Nagaraja R, Schlessinger D, Jackson AU, Tuomilehto J, Collins FS, Boehnke M, Mohlke KL. Common variants near MC4R are associated with fat mass, weight and risk of obesity. *Nat Genet* 2008; **40**: 768-775 [PMID: 18454148 DOI: 10.1038/ng.140]
 - 17 **Huszar D**, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* 1997; **88**: 131-141 [PMID: 9019399 DOI: 10.1016/S0092-8674(00)81865-6]
 - 18 **Farooqi IS**, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. *N Engl J Med* 2003; **348**: 1085-1095 [PMID: 12646665 DOI: 10.1056/NEJMoa022050]
 - 19 **Branson R**, Potoczna N, Kral JG, Lentjes KU, Hoehe MR, Horber FF. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. *N Engl J Med* 2003; **348**: 1096-1103 [PMID: 12646666 DOI: 10.1056/NEJMoa021971]
 - 20 **Magro F**, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, Villanacci V, Becheanu G, Borrallho Nunes P, Cathomas G, Fries W, Jouret-Mourin A, Mescoli C, de Petris G, Rubio CA, Shepherd NA, Vieth M, Eliakim R; European Society of Pathology (ESP); European Crohn's and Colitis Organisation (ECCO). European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis* 2013; **7**: 827-851 [PMID: 23870728 DOI: 10.1016/j.crohns.2013.06.001]
 - 21 **Pouw RE**, Bisschops R, Gecse KB, de Hertogh G, Iacucci M, Rutter M, Barret M, Biermann K, Czakó L, Hucl T, Jansen M, Savarino E, Spaander MCW, Schmidt PT, Dinis-Ribeiro M, Vieth M, van Hooft JE. Endoscopic tissue sampling - Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. *Endoscopy* 2021; **53**: 1261-1273 [PMID: 34715702 DOI: 10.1055/a-1671-6336]
 - 22 **Kishi M**, Hirai F, Takatsu N, Hisabe T, Takada Y, Beppu T, Takeuchi K, Naganuma M, Ohtsuka K, Watanabe K, Matsumoto T, Esaki M, Koganei K, Sugita A, Hata K, Futami K, Ajioka Y, Tanabe H, Iwashita A, Shimizu H, Arai K, Suzuki Y, Hisamatsu T. A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation. *J Gastroenterol* 2022; **57**: 246-266 [PMID: 35235037 DOI: 10.1007/s00535-022-01862-y]
 - 23 **Rutgeerts P**, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2005; **353**: 2462-2476 [PMID: 16339095 DOI: 10.1056/NEJMoa050516]
 - 24 **Mary JY**, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut* 1989; **30**: 983-989 [PMID: 2668130 DOI: 10.1136/gut.30.7.983]
 - 25 **Di Filippo C**, Zippo MV, Maisto R, Trotta MC, Siniscalco D, Ferraro B, Ferraraccio F, La Motta C, Sartini S, Cosconati S, Novellino E, Gesualdo C, Simonelli F, Rossi S, D'Amico M. Inhibition of ocular aldose reductase by a new benzofuroxane derivative ameliorates rat endotoxic uveitis. *Mediators Inflamm* 2014; **2014**: 857958 [PMID: 25435715 DOI: 10.1155/2014/857958]
 - 26 **Getting SJ**, Gibbs L, Clark AJ, Flower RJ, Perretti M. POMC gene-derived peptides activate melanocortin type 3 receptor on murine macrophages, suppress cytokine release, and inhibit neutrophil migration in acute experimental inflammation. *J Immunol* 1999; **162**: 7446-7453 [PMID: 10358199]

- 27 **Getting SJ**, Di Filippo C, Christian HC, Lam CW, Rossi F, D'Amico M, Perretti M. MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct. *J Leukoc Biol* 2004; **76**: 845-853 [PMID: 15277567 DOI: 10.1189/jlb.0306175]
- 28 **Getting SJ**, Lam CW, Chen AS, Grieco P, Perretti M. Melanocortin 3 receptors control crystal-induced inflammation. *FASEB J* 2006; **20**: 2234-2241 [PMID: 17077300 DOI: 10.1096/fj.06-6339com]
- 29 **Ellacott KL**, Murphy JG, Marks DL, Cone RD. Obesity-induced inflammation in white adipose tissue is attenuated by loss of melanocortin-3 receptor signaling. *Endocrinology* 2007; **148**: 6186-6194 [PMID: 17901224 DOI: 10.1210/en.2007-0699]
- 30 **Buggy JJ**. Binding of alpha-melanocyte-stimulating hormone to its G-protein-coupled receptor on B-lymphocytes activates the Jak/STAT pathway. *Biochem J* 1998; **331** (Pt 1): 211-216 [PMID: 9512481 DOI: 10.1042/bj3310211]
- 31 **Sandborn WJ**, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. *N Engl J Med* 2017; **376**: 1723-1736 [PMID: 28467869 DOI: 10.1056/NEJMoa1606910]
- 32 **Xu Y**, Guan X, Zhou R, Gong R. Melanocortin 5 receptor signaling pathway in health and disease. *Cell Mol Life Sci* 2020; **77**: 3831-3840 [PMID: 32248247 DOI: 10.1007/s00018-020-03511-0]
- 33 **Maisto R**, Gesualdo C, Trotta MC, Grieco P, Testa F, Simonelli F, Barcia JM, D'Amico M, Di Filippo C, Rossi S. Melanocortin receptor agonists MCR(1-5) protect photoreceptors from high-glucose damage and restore antioxidant enzymes in primary retinal cell culture. *J Cell Mol Med* 2017; **21**: 968-974 [PMID: 27998021 DOI: 10.1111/jcmm.13036]
- 34 **Trotta MC**, Maisto R, Alessio N, Hermenean A, D'Amico M, Di Filippo C. The Melanocortin MC5R as a New Target for Treatment of High Glucose-Induced Hypertrophy of the Cardiac H9c2 Cells. *Front Physiol* 2018; **9**: 1475 [PMID: 30416452 DOI: 10.3389/fphys.2018.01475]
- 35 **Rossi S**, Maisto R, Gesualdo C, Trotta MC, Ferraraccio F, Kaneva MK, Getting SJ, Surace E, Testa F, Simonelli F, Grieco P, Merlino F, Perretti M, D'Amico M, Di Filippo C. Activation of Melanocortin Receptors MC 1 and MC 5 Attenuates Retinal Damage in Experimental Diabetic Retinopathy. *Mediators Inflamm* 2016; **2016**: 7368389 [PMID: 26949291 DOI: 10.1155/2016/7368389]
- 36 **Montero-Melendez T**. ACTH: The forgotten therapy. *Semin Immunol* 2015; **27**: 216-226 [PMID: 25726511 DOI: 10.1016/j.smim.2015.02.003]
- 37 **Grieco P**, Han G, Weinberg D, Van der Ploeg LH, Hruba VJ. Design and synthesis of highly potent and selective melanotropin analogues of SHU9119 modified at position 6. *Biochem Biophys Res Commun* 2002; **292**: 1075-1080 [PMID: 11944925 DOI: 10.1006/bbrc.2002.6739]
- 38 **Can VC**, Locke IC, Kaneva MK, Kerrigan MJP, Merlino F, De Pascale C, Grieco P, Getting SJ. Novel anti-inflammatory and chondroprotective effects of the human melanocortin MC1 receptor agonist BMS-470539 dihydrochloride and human melanocortin MC3 receptor agonist PG-990 on lipopolysaccharide activated chondrocytes. *Eur J Pharmacol* 2020; **872**: 172971 [PMID: 32004526 DOI: 10.1016/j.ejphar.2020.172971]
- 39 **Gantz I**, Konda Y, Tashiro T, Shimoto Y, Miwa H, Munzert G, Watson SJ, DelValle J, Yamada T. Molecular cloning of a novel melanocortin receptor. *J Biol Chem* 1993; **268**: 8246-8250 [PMID: 8463333]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Telephone: +1-925-3991568
E-mail: office@baishideng.com
Help Desk: <https://www.f6publishing.com/helpdesk>
<https://www.wjgnet.com>

